Fighting Cancer Every Step of the Way™

Vigilant Biosciences is transforming the early detection and intervention of cancer.

Learn More
Media Kit

Introducing the OraMark™ Laboratory Developed Test for the U.S!

Learn More about OraMark™
vb-homepage-image3

Dedicated to Early Intervention. And Life.™


Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The OncAlert™ Oral Cancer product line uses patented technology based on clinical science that shows possible presence of oral cancer in its earliest stages… even before visual or physical symptoms develop.

Learn More
Did You Know?

When diagnosed early, oral cancer patients have an 80 to 90% survival rate.

Unfortunately, over 40% of those diagnosed with oral cancer will die within five years due to these cases being discovered as a late stage malignancy.

Learn More

At A Glance

Transforming Early Detection

Vigilant Biosciences™ products are based on patented technology that detects specific protein markers clinically shown to aid in the detection of early stage cancers, even prior to observation of visual or physical symptoms... more


Easy-to-Use and Non-Invasive

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more


Accurate and Objective Results at the Point-of-Care or in the Laboratory

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more

MORE ABOUT VIGILANT'S ONCALERT™ TECHNOLOGY

News + Press

  • sunsentinel

    Startup sector expects to flex more muscle in 2017

    When Matthew Kim, founder and CEO of Vigilant Biosciences in Fort Lauderdale started his company in 2011, he quickly found funding to be a serious challenge. Ultimately, he persuaded an out-of-state investor to help, but in his most recent financing…more

  • vb-400x210

    Vigilant Biosciences to Present at Medtech Showcase 2017 and BioLink 2017 China Healthcare Industry Investment and Licensing Conference

    FORT LAUDERDALE, Fla., Jan. 6, 2017 /PRNewswire/ —  Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced that Matthew H.J. Kim, Founder, Chairman and Chief Executive Officer, will present at two…more

  • vb-400x210

    Vigilant Biosciences Announces OncAlert® Oral Cancer Product Line Now Shipping

    FORT LAUDERDALE, Fla. – December 20, 2016 – Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced that its OncAlert® Oral Cancer product line is now shipping…more

  • vb-400x210

    Vigilant Biosciences Announces New Distribution Partnership Agreements for OncAlert® Oral Cancer Product Line for Spain, Portugal and Germany

    FORT LAUDERDALE, Fla. and DUSSELDORF, Germany – November 14, 2016 – Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced exclusive multi-year distribution agreement for sales…more


©2011-2017 Vigilant Biosciences, Inc. All Rights Reserved.

×